GeoVax Labs, Inc. (Nasdaq: GOVX) today reported financial results for the quarter ended June 30, 2026, and provided a business update emphasizing continued execution toward the planned initiation of a pivotal GEO-MVA immunobridging study under an expedited regulatory pathway. The company also highlighted ongoing development of its Gedeptin immuno-oncology program.
During the second quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study, following formal Scientific Advice discussions with the European Medicines Agency (EMA). Activities included clinical study readiness, manufacturing preparedness, and stakeholder engagement.
David A. Dodd, Chairman and CEO of GeoVax, said, 'During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study. Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.'
GeoVax believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity. The company continued engagement with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
In its oncology pipeline, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism may complement PD-1-based therapies such as Merck's Keytruda by improving responsiveness in immunologically resistant tumors. GeoVax continues to strengthen the program's strategic positioning through its exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, for the same period in 2025. The company reported no revenue from government contracts in the 2026 period, compared to $852,282 in the prior-year period, reflecting the termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program. Research and development expenses decreased to $3.1 million from $4.7 million, primarily due to lower costs associated with discontinued BARDA activities and reduced spending on GEO-CM04S1. General and administrative expenses decreased to $1.3 million from $1.5 million, driven by lower investor relations consulting costs and reduced stock-based compensation.
As of June 30, 2026, GeoVax reported cash and cash equivalents of approximately $3.1 million, consistent with $3.1 million at December 31, 2025.
Additional information is included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For more details on GeoVax's programs, visit www.geovax.com.
